Show simple item record

Antidepresivi - mitovi, činjenice i perspektive

dc.creatorObradović, Aleksandar
dc.creatorSavić, Miroslav
dc.date.accessioned2019-09-02T12:01:49Z
dc.date.available2019-09-02T12:01:49Z
dc.date.issued2017
dc.identifier.issn0004-1963
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/2976
dc.description.abstractAntidepressants are one of the most widely used and criticized drug classes. Long-term effects leading to clinical efficacy of antidepressants in indications such as depression or anxiety disorders are poorly understood. The analysis of clinical trials suggests that, to a substantial degree, listening to antidepressants means hearing placebo. The precipitation of suicidal ideation is a possibility that needs to be considered when introducing antidepressants, especially in young patients. The discontinuation symptoms following cessation of treatment emerge frequently, and essentially are manifestations of withdrawal. Many, if not most, patients require multiple modifications in treatment in order to reach remission and avoid relapse or recurrence. However, these drugs are needed in clinical practice, and it is of paramount importance to precisely tailor treatment with antidepressants and adjunctive drugs to achieve optimal efficacy with minimal adverse effects. There are also hopes that novel drugs with rapid ketamine-like antidepressant actions may be introduced in the near future, thus solving the issue of acute management of severe depressions.en
dc.description.abstractAntidepresivi spadaju u lekove koji su u isto vreme najviše korišćeni i kritikovani. Dugotrajni efekti antidepresiva koji obezbeđuju kliničku efikasnost u indikacijama kao što su depresija ili anksiozni poremećaji slabo su razjašnjeni. Analiza rezultata kliničkih ispitivanja sugeriše da antidepresivnom dejstvu ovih lekova, u znatnom obimu, doprinosi placebo efekat. Precipitacija misli o suicidu predstavlja mogućnost koja se mora temeljno razmotriti prilikom uvođenja antidepresiva, posebno kod mladih pacijenata. Simptomi diskontinuacije nakon prekida terapije javljaju se često, i suštinski predstavljaju manifestacije obustave. Višestruke modifikacije tretmana, a u cilju postizanja remisije i izbegavanja relapsa ili recidiva, zahtevaju brojni pacijenti, ako ne i većina njih. Uprkos svemu, ovi lekovi jesu neophodni u kliničkoj praksi, i precizno prilagođavanje tretmana antidepresivima i adjuvantnim lekovima od neprocenjivog je značaja u cilju postizanja optimalne efikasnosti sa minimumom neželjenih efekata. Dodatno, postoje očekivanja da bi novi lekovi sa brzim antidepresivnim dejstvom sličnim ketaminu mogli da budu uvedeni u skorijoj budućnosti, čime bi se prevazišao problem akutnog zbrinjavanja teških depresija.sr
dc.publisherSavez farmaceutskih udruženja Srbije, Beograd
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by-sa/4.0/
dc.sourceArhiv za farmaciju
dc.subjectmechanism of actionen
dc.subjectplacebo effecten
dc.subjectsuicidalityen
dc.subjectdiscontinuationen
dc.subjectmehanizam dejstvasr
dc.subjectplacebo efekatsr
dc.subjectsuicidalnostsr
dc.subjectdiskontinuacijasr
dc.titleAntidepressants: Myths, facts and perspectivesen
dc.titleAntidepresivi - mitovi, činjenice i perspektivesr
dc.typearticle
dc.rights.licenseBY-SA
dcterms.abstractСавић, Мирослав; Обрадовић, Aлександар; Aнтидепресиви - митови, чињенице и перспективе; Aнтидепресиви - митови, чињенице и перспективе;
dc.citation.volume67
dc.citation.issue5
dc.citation.spage291
dc.citation.epage301
dc.citation.other67(5): 291-301
dc.citation.rankM53
dc.identifier.doi10.5937/arhfarm1705291O
dc.identifier.scopus2-s2.0-85067565559
dc.identifier.fulltexthttps://farfar.pharmacy.bg.ac.rs//bitstream/id/1585/2974.pdf
dc.identifier.rcubconv_583
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record